Avacta GroupAVCTF 13 Market Cap is $448.38 Mil as of Jun. 25, 2026. GuruFocus rates AVCTF with a GF Score™ of 13/100 and a GF Value™ of $0.65 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,431 Biotechnology companies, Avacta Group ranks better than 70.37% on this metric.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Avacta Group's share price for the quarter that ended in Dec. 2025 was $0.77795. Avacta Group's Shares Outstanding (EOP) for the quarter that ended in Dec. 2025 was 437.63 Mil. Therefore, Avacta Group's market cap for the quarter that ended in Dec. 2025 was $340.46 Mil.
Avacta Group's quarterly market cap
declined
from Dec. 2024 ($207.14 Mil) to Jun. 2025 ($156.79 Mil) but then
increased
from Jun. 2025 ($156.79 Mil) to Dec. 2025 ($340.46 Mil).
Avacta Group's annual market cap
declined
from Dec. 2023 ($455.96 Mil) to Dec. 2024 ($207.14 Mil) but then
increased
from Dec. 2024 ($207.14 Mil) to Dec. 2025 ($340.46 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Avacta Group's Enterprise Value for Today is $445.82 Mil.
Avacta Group (OTCPK:AVCTF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Avacta Group Market Cap Related Terms
Avacta Group Market Cap Historical Data
* Premium members only.
The historical data trend for Avacta Group's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Avacta Group's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avacta Group Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Avacta Group's Market Cap distribution charts can be found below:
* The bar in red indicates where Avacta Group's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Avacta Group's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avacta Group (AVCTF) has a Market Cap of $448.38 Mil as of Jun. 25, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Avacta Group and its competitors. According to the industry distribution chart, Avacta Group ranks #424 out of 1431 companies in the Biotechnology industry, placing it in the top 29.6%.
Is Avacta Group's Market Cap too high?
Avacta Group's current Market Cap is $448.38 Mil. The Biotechnology industry median Market Cap is 117.63. Avacta Group's value of $448.38 Mil is 281.2% above this industry median. Based on the distribution chart, Avacta Group ranks #424 out of 1431 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Avacta Group has a GF Score™ of 13/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Avacta Group's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Avacta Group ranks #424 out of 1431 companies for Market Cap. This puts Avacta Group in the upper half of its industry. The industry median Market Cap is 117.63. Avacta Group's value of $448.38 Mil is 281.2% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 117.63, based on 1,431 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avacta Group's current Market Cap of $448.38 Mil is 281.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Avacta Group and its competitors. For the Biotechnology industry, the median Market Cap is 117.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avacta Group's current Market Cap is $448.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avacta Group stock overvalued right now?
Based on GuruFocus' analysis, Avacta Group (AVCTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.65, compared to a current price of $1.00 — trading 53.8% above its estimated fair value. The current Market Cap is $448.38 Mil and 281.2% above the Biotechnology industry median of 117.63. Avacta Group's overall GF Score™ is 13/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Avacta Group (AVCTF), the current Market Cap is $448.38 Mil as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avacta Group (AVCTF) Overvalued in 2026?
Based on GuruFocus' analysis, Avacta Group stock appears to be overvalued.
The current stock price of $1.00 is trading 53.8% above its estimated GF Value™ of $0.65.
GuruFocus considers Avacta Group to be Significantly Overvalued.
Key valuation signals for AVCTF:
Market Cap: $448.38 Mil
GF Value™: $0.65 vs. price of $1.00 (53.8% above fair value)
Industry Position: 281.2% above the Biotechnology median (#424 of 1431)
No single metric tells the full story. See the AVCTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avacta Group PLC is a clinical-stage life sciences company expanding the reach of potent cancer therapies with the pre-CISION platform. pre-CISION is a proprietary warhead delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate potent warheads in the tumor microenvironment while sparing normal tissues. The company's pipeline consists of pre-CISION peptide drug conjugates (PDC) or Affimer drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing benefits over traditional antibody drug conjugates. The firm has one reportable segment, Therapeutics, which is engaged in the development of novel cancer therapies harnessing its proprietary technology. Geographically, it derives revenue from South Korea.
13GF Score
Get the complete analysis for AVCTF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVCTF has been successfully added to your 
